【norwalk garbage pick up schedule】Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?
Jazz Pharmaceuticals plc
JAZZ is norwalk garbage pick up schedulescheduled to report first-quarter 2017 results on May 9, after the market closes.
Jazz’s shares have significantly outperformed the Zacks classified Medical-Drugs industry so far this year. Specifically, the stock gained 46.4% during the period, while the industry recorded an increase of 5.3%.
Jazz has quite an encouraging earnings track record. Last quarter, the company comfortably surpassed expectations with a positive earnings surprise of 15.76%. In fact, the company beat estimates in all the last four quarters with an average positive earnings surprise of 25.34%.
Jazz Pharmaceuticals PLC Price and EPS Surprise
Jazz Pharmaceuticals PLC Price and EPS Surprise | Jazz Pharmaceuticals PLC Quote
Let’s see how things have shaped up for this quarter.
Factors at Play
At the first-quarter conference call, focus will be on the performance of Jazz’s lead product, Xyrem, for cataplexy and excessive daytime sleepiness (EDS). Investors will also be looking out for the company’s pipeline progress. Defitelio’s sales ramp-up in the U.S., patent litigations related to Xyrem and the company’s business development plans are also expected to draw attention.
Xyrem should deliver strong performance in the first quarter. The company is also striving to expand Xyrem’s label and is currently conducting a phase II/III EXPRESS study in children and adolescents who have cataplexy with narcolepsy. In Apr 2017, the company announced positive top-line efficacy results from the study.
Defitelio (veno-occlusive disease) was launched in the U.S. in early Apr 2016 and the sales drug have picked up pace. The company reported that 117 unique accounts ordered Defitileo in fourth-quarter 2016, with 71% reordering since its launch. At the fourth-quarter 2016 conference call, the company issued its guidance for Defitelio/defibrotide net sales for 2017 in the range of $130–$150 million. The company expects $45–$55 million sales in U.S. in 2017. Meanwhile, in Jan 2017 the company initiated a phase III clinical study on Defitelio for the potential prevention of veno-occlusive disease (VOD) in high-risk adult and pediatric patients.
However, Jazz has been facing challenges in building sufficient inventory levels for Erwinaze due to constrained manufacturing capacity. The company may continue to experience further supply disruptions in certain markets, including the U.S., in the first quarter and beyond.
On the other hand, in Apr 2017, the company announced positive efficacy results from a global multicenter, phase III TONES 2 study, in adult patients with excessive sleepiness associated with narcolepsy. In the study, JZP-110 demonstrated highly statistically significant improvement in the co-primary endpoints.
In Oct 2016, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos, which it finished in early Apr 2017. We believe Vyxeos has multi-million dollar potential. We expect the company to update on Vyxeos at the first-quarter conference call.
Earnings Whispers
Our proven model does not conclusively show that Jazz will beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to be able to beat estimates. Unfortunately, this is not the case here as you will see below.
Zacks ESP:
The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $1.32. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank:
Jazz currently carries a Zacks Rank #4 (Sell). As it is, we caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Other Stocks That Warrant a Look
Here are some health care stocks that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Conatus Pharmaceuticals Inc. CNAT is scheduled to release results on May 4. The company has an Earnings ESP of +57.14% and a Zacks Rank #3. You can see
the complete list of today’s Zacks #1 Rank stocks here
.
ImmunoGen, Inc. IMGN is scheduled to release results on May 5. The company has an Earnings ESP of +8.33% and a Zacks Rank #3.
FIBROGEN INC FGEN is scheduled to release results on May 8. The company has an Earnings ESP of +23.81% and a Zacks Rank #3.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
Conatus Pharmaceuticals Inc. (CNAT): Free Stock Analysis Report
Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report
ImmunoGen, Inc. (IMGN): Free Stock Analysis Report
FibroGen, Inc (FGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
View comments
-
CanWel Building Materials Group (TSE:CWX) Shareholders Have Felt Some Pain With A 19% Loss On Their InvestmentEnergy Fuels Inc.'s (TSE:EFR) Intrinsic Value Is Potentially 96% Above Its Share PriceH2O Innovation Secures 7 New Projects, Totalling $7.6 M and Received Notice of Cancellation for One ProjectLabrador Iron Ore Royalty Corporation Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For Next YearSilver Price Daily Forecast – Silver Attempts To Break Through The Key Resistance LevelVishay Precision Group, Inc. to Host Earnings CallThai Airways rescue plan is its last chance, says PMGlobal core material market size to record unprecedented growth through 2025SHAREHOLDER ALERT: TUFN EHTH R: The Law Offices of Vincent Wong Reminds Investors of Important Class Action DeadlinesCoronavirus Could Hold Up Annual Ocean Shipping Contracts
下一篇:Exxon CEO sticks to spending targets as oil prices tumble
- ·Loop Industries Reports Fourth Quarter Consolidated Financial Results of Fiscal 2020 and Provides Updates on Business Developments
- ·Calculating The Fair Value Of Asanko Gold Inc. (TSE:AKG)
- ·CRON INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of a Filing Deadline in a Securities Class Action Against Cronos Group Inc.
- ·As coronavirus misinformation spreads on social media, Facebook removes posts
- ·Americans have a mix of concern and hope about the economy
- ·Visa's (V) Program to Aid Asia Pacific Startups Thrive Globally
- ·Calculating The Intrinsic Value Of FFI Holdings Limited (ASX:FFI)
- ·IRS offers new relief options to help with tax bills during coronavirus pandemic
- ·CMA CGM Donates 200,000 Face Masks
- ·Cheniere seeks U.S. permission to put Oklahoma Midship natgas pipe in service
- ·Is It Smart To Buy Garmin Ltd. (NASDAQ:GRMN) Before It Goes Ex-Dividend?
- ·Freedom Trail and Black Heritage Trail Bring History Into Homes Near and Far
- ·Ferrari (RACE) Q3 Earnings Beat Estimates
- ·Toll Brothers Makes Wedbush's Best Ideas List: Here's Why
- ·Meal delivery firms branch out into groceries during crisis
- ·IRS offers new relief options to help with tax bills during coronavirus pandemic
- ·Former Walmart CEO says coronavirus will challenge department stores
- ·WRAPUP 1-Standard U.S. economic weapons may be inadequate for coronavirus crisis
- ·Dow Jumps Over 5% as Stocks Finally Bounce Back
- ·Buying a House? 4 Things to Take Off Your Must-Have List Now
- ·Global Automotive Plastics Markets, 2020-2027 - Focus on ABS, PP, PU, PVC, PE, PC, PMMA, PA & Others
- ·United Kingdom Cardiac Rhythm Management Devices Market Outlook to 2025 - Cardiac Resynchronisation Therapy (CRT), Implantable Cardioverter Defibrillators (ICD), Implantable Loop Recorders (ILR) and Pacemakers
- ·Sun Summit Minerals Phase 2 Drilling Update and Completion of IP Survey at the Buck Property
- ·HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages VMware (VMW) Investors Who Have Suffered Significant Losses to Contact its Attorneys: Securities Fraud Class Action Deadlines Established
- ·The TriNet Group (NYSE:TNET) Share Price Has Gained 256%, So Why Not Pay It Some Attention?
- ·Avista (AVA) Misses Q3 Earnings and Revenue Estimates
- ·A2Z Technologies Lists on Frankfurt Stock Exchange
- ·Insider Buying: The Mitchell Services Limited (ASX:MSV) Executive Chairman Just Bought AU$53k Worth Of Shares
- ·EXPLAINER-Why is Israel holding its third election in a year?
- ·The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Liberty Oilfield Services Inc. (LBRT)
- ·Ramping up COVID-19 testing earlier would have helped the UK, top adviser says
- ·Shift Announces Its Intention to Commence an Offer to Exchange Its Publicly Traded Warrants
- ·The Benchmark Company Announces Upcoming Technology One on One Virtual Investor Conference
- ·240,000 U.S. Virus Deaths Don't Have to Happen
- ·Cheniere seeks U.S. permission to put Oklahoma Midship natgas pipe in service
- ·StockBeat: Virus Derails Intu's Rescue Plan